Charles Schwab Investment Management Inc. Purchases 5,639 Shares of Enfusion, Inc. (NYSE:ENFN)

Charles Schwab Investment Management Inc. grew its position in shares of Enfusion, Inc. (NYSE:ENFN) by 1.5% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 371,151 shares of the company’s stock after buying an additional 5,639 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.29% of Enfusion worth $3,823,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ENFN. Paloma Partners Management Co bought a new stake in Enfusion during the third quarter worth $157,000. Centiva Capital LP increased its position in shares of Enfusion by 5.0% during the 3rd quarter. Centiva Capital LP now owns 25,596 shares of the company’s stock valued at $243,000 after purchasing an additional 1,227 shares during the last quarter. Azora Capital LP increased its position in shares of Enfusion by 6.8% during the 3rd quarter. Azora Capital LP now owns 29,827 shares of the company’s stock valued at $283,000 after purchasing an additional 1,890 shares during the last quarter. Rhumbline Advisers raised its stake in shares of Enfusion by 3.0% during the 4th quarter. Rhumbline Advisers now owns 62,464 shares of the company’s stock worth $643,000 after purchasing an additional 1,796 shares during the period. Finally, Martingale Asset Management L P boosted its holdings in shares of Enfusion by 26.2% in the 3rd quarter. Martingale Asset Management L P now owns 74,360 shares of the company’s stock worth $706,000 after buying an additional 15,424 shares during the last quarter. Hedge funds and other institutional investors own 81.05% of the company’s stock.

Insider Activity at Enfusion

In other news, COO Neal Pawar sold 2,769 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $11.48, for a total value of $31,788.12. Following the sale, the chief operating officer now directly owns 1,231,627 shares of the company’s stock, valued at approximately $14,139,077.96. This represents a 0.22 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Bronwen Bastone sold 3,126 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $11.38, for a total transaction of $35,573.88. Following the completion of the transaction, the insider now owns 221,875 shares of the company’s stock, valued at $2,524,937.50. This trade represents a 1.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 77,346 shares of company stock worth $868,109. Corporate insiders own 36.44% of the company’s stock.

Enfusion Stock Performance

Shares of ENFN opened at $11.18 on Thursday. Enfusion, Inc. has a fifty-two week low of $7.83 and a fifty-two week high of $11.80. The business has a 50-day moving average of $11.17 and a 200 day moving average of $10.16. The firm has a market cap of $1.44 billion, a P/E ratio of 279.44, a price-to-earnings-growth ratio of 1.85 and a beta of 0.95.

Enfusion (NYSE:ENFN) last posted its earnings results on Monday, March 3rd. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.02). Enfusion had a return on equity of 6.67% and a net margin of 1.70%. The business had revenue of $52.94 million during the quarter, compared to analysts’ expectations of $53.98 million. As a group, research analysts predict that Enfusion, Inc. will post 0.06 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently issued reports on ENFN shares. Stifel Nicolaus raised their price objective on shares of Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, December 18th. William Blair restated a “market perform” rating on shares of Enfusion in a research note on Monday, January 13th. Finally, Piper Sandler upped their price objective on Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a research note on Monday, December 23rd.

Enfusion Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.